The Clinical Implications of ADAMTS13 Function: The Perspectives of Haemostaseologists

Thrombosis Research

Volumn 132, Issue 4, 2013, Pages 403-407

  Rangarajan, Savita ^a   Kessler, Craig ^b   Aledort, Louis ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; HUMAN; INFLAMMATION; LIVER DISEASE; MALARIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SICKLE CELL ANEMIA; THROMBOSIS;

ADAM PROTEINS; ANIMALS; BLOOD PLATELETS; HUMANS; VON WILLEBRAND FACTOR;

EID: 84885174569     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.07.027     Document Type: Review

References (58)

1. M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, and B. Brenner Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Engl J Med 339 1998 1578 1584
2. J.L. Moake, C.K. Rudy, J.H. Troll, M.J. Weinstein, N.M. Colannino, and J. Azocar Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura N Engl J Med 307 1982 1432 1435
3. J.A. Dent, S.D. Berkowitz, J. Ware, C.K. Kasper, and Z.M. Ruggeri Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor Proc Natl Acad Sci 87 1990 6306 6310
4. M. Uemura, K. Tatsumi, M. Matsumoto, M. Fujimoto, T. Matsuyama, and M. Ishikawa Localization of ADAMTS13 to the stellate cells of human liver Blood 106 2005 922 924
5. L. Liu, H. Choi, A. Bernardo, A.l. Bergeron, L. Nolasco, and C. Ruan Plateletâ derived VWFâ cleaving metalloprotease ADAMTSâ 13 J Thromb Haemost 3 2005 2536 2544
6. D. Shang, X.W. Zheng, M. Niiya, and X.L. Zheng Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts Blood 108 2006 2207
7. L.A. Sporn, V.J. Marder, and D.D. Wagner Inducible secretion of large, biologically potent von Willebrand factor multimers Cell 46 1986 185 190
8. J. Dong, J.L. Moake, L. Nolasco, A. Bernardo, W. Arcenaux, and C.N. Shrimpton ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions Blood 100 2002 4033 4039
9. A. Chauhan, T. Goerge, S. Schneider, and D. Wagner Formation of platelet strings and microthrombi in the presence of ADAMTSâ 13 inhibitor does not require Pâ selectin or β3 integrin J Thromb Haemost 5 2007 583 589
10. A.K. Chauhan, D.G. Motto, C.B. Lamb, W. Bergmeier, M. Dockal, and B. Plaimauer Systemic antithrombotic effects of ADAMTS13 J Exp Med 203 2006 767 776
11. H.P. Adams, M.B. Effron, J. Torner, A. Davalos, J. Frayne, and P. Teal Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial Stroke 39 2008 87 99
12. C. Kleinschnitz, S.F. De Meyer, T. Schwarz, M. Austinat, K. Vanhoorelbeke, and B. Nieswandt Deficiency of von Willebrand factor protects mice from ischemic stroke Blood 113 2009 3600 3603
13. C. Kleinschnitz, M. Pozgajova, and M. Pham Targeting Platelets in Acute Experimental Stroke Circulation 115 2007 2323 2330
14. B.Q. Zhao, A.K. Chauhan, M. Canault, M. Bendszus, B. Nieswandt, and G. Stoll von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke Blood 114 2009 3329 3334
15. P. Libby, I.S. Patten, J.J. Yang, and M. Dockal Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
16. G. Heper, S.N. Murat, T. Durmaz, and F. Kalkan Prospective evaluation of von Willebrand factor release after multiple and single stenting Angiology 55 2004 177 186
17. K.W. Lee, G.Y.H. Lip, and M. Tayebjee Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes Blood 105 2005 526 532
18. G. Montalescot, F. Philippe, A. Ankri, W. Foster, and A.D. Blann Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin Circulation 98 1998 294 299
19. S.G. Thompson, J. Kienast, S.D.M. Pyke, E. Vicaut, E. Bearez, and J.E. Poulard Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris N Engl J Med 332 1995 635 641
20. K. Kaikita, K. Soejima, M. Matsukawa, F. Haverkate, and J.C. Van de loo Reduced von Willebrand factorâ cleaving protease (ADAMTS13) activity in acute myocardial infarction J Thromb Haemost 4 2006 2490 2493
21. M. Matsukawa, K. Kaikita, K. Soejima, T. Nakagaki, and H. Ogawa Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction Am J Cardiol 100 2007 758 763
22. S. Fuchigami, K. Kaikita, K. Soejima, A.J. de Jong, J.W. Deckers, and D. Poldermans Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina Thromb Res 122 2008 618 623
23. T. Bongers, E. de Bruijne, D. Dippel, M. Matsukawa, T. Honda, and k. Tsujita Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients Atherosclerosis 207 2009 250 254
24. M. Miura, K. Kaikita, M. Matsukawa, K. Soejima, S. Fuchigami, and Y. Miyazaki Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease Thromb Haemost 103 2010 623 629
25. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
26. T. Uemura, K. Kaikita, H. Yamabe, K. Soejima, M. Matsukawa, and S. Fuchgami Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation Thromb Res 124 2009 28 32
27. M.K. Freynhofer, V. Bruno, R. Jarai, S. Gruber, T. Höchtl, and I. Brozovic Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation Thromb Haemost 105 2011 435 443
28. C.J. Lowenstein, C.N. Morrell, and M. Yamakuchi Regulation of Weibel-Palade body exocytosis Trends Cardiovasc Med 15 2005 302 308
29. A.K. Chauhan, J. Kisucka, A. Brill, M.T. Walsh, F. Scheiflinger, and D.D. Wagner ADAMTS13: a new link between thrombosis and inflammation J Exp Med 205 2008 2065 2074
30. J. Kremer Hovinga, S. Zeerleder, P. Kessler, T. Romani de Wit, J. van Mourik, and C.E. Hack ADAMTSâ 13, von Willebrand factor and related parameters in severe sepsis and septic shock J Thromb Haemost 5 2007 2284 2290
31. R.A. Claus, C.L. Bockmeyer, U. Budde, K. Kentouche, M. Sossdorf, and T. Hilberg Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure Thromb Haemost 101 2009 239 247
32. C.L. Bockmeyer, P.A. Reuken, T.P. Simon, D.T. Jamison, and C.J. Murray ADAMTS13 activity is decreased in a septic porcine model Thromb Haemost 105 2011 145 153
33. A.D. Lopez, C.D. Mathers, M. Ezzati, U. Budde, W. Losche, and M. Bauer Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data Lancet 367 2006 1747 1757
34. M.J. Hollestelle, C. Donkor, E.A. Mantey, S.J. Chakravorty, A. Craig, and A.O. Akoto von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation Br J Haematol 133 2006 562 569
35. S.C. Wassmer, V. Combes, F.J. Candal, I. Juhan-Vaque, and G.E. Grau Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum Infect Immun 74 2006 645 653
36. Q. de Mast, E. Groot, P.B. Asih, D. Syfruddin, M. Oosting, and S. Sebastian ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria Am J Trop Med Hyg 80 2009 492 498
37. D. Larkin, B. De Laat, P.V. Jenkins, J. Bunn, A.G. Craig, and V. Terraube Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition PLoS Pathog 5 2009 e1000349
38. E.C. Löwenberg, P. Charunwatthana, S. Cohen, B.J. Van den Born, J.C. Meijers, and E.B. Yunus Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13 Thromb Haemost 103 2010 181 187
39. K. Soejima, N. Mimura, M. Hiroshima, H. Maeda, T. Hamamoto, and T. Nakagaki A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor - Cleaving Protease? J Biochem 130 2001 475 480
40. T. Lisman, S.H. Caldwell, A.K. Burroughs, P.G. Northup, M. Senzolo, and R.T. Stravitz Hemostasis and thrombosis in patients with liver disease: the ups and downs J Hepatol 53 2010 362 371
41. F. Schaffner, and H. Poper Capillarization of hepatic sinusoids in man Gastroenterology 44 1963 239
42. M. Hattori, Y. Fukuda, M. Imoto, Y. Koyama, Y. Nakano, and F. Urano Histochemical properties of vascular and sinusoidal endothelial cells in liver diseases J Gastroenterol 26 1991 336 343
43. P.M. Mannucci, M.T. Canciani, I. Forza, F. Lussana, A. Lattuada, and E. Rossi Changes in health and disease of the metalloprotease that cleaves von Willebrand factor Blood 98 2001 2730 2735
44. M. Uemura, Y. Fujimura, M. Matsumoto, H. Ishizashi, S. Kato, and T. Matsuyama Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis Thromb Haemost 99 2008 1019 1029
45. H.B. Feys, M.T. Canciani, F. Peyvandi, H. Deckmyn, K. Vanhoorelbeke, and P.M. Mannucci ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis Br J Haematol 138 2007 534 540
46. T. Lisman, T.N. Bongers, J. Adelmeijer, H.L. Janssen, M.P. de Maat, and P.G. de Groot Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity Hepatology 44 2006 53 61
47. A. Bernardo, C. Ball, L. Nolasco, J.F. Moake, and J.F. Dong Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow Blood 104 2004 100 106
48. W. Cao, M. Niiya, X. Zheng, D.Z. Shang, and X.L. Zheng Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells J Thromb Haemost 6 2008 1233 1235
49. M. Uemura, T. Matsuyama, M. Ishikawa, M. Fujimoto, H. Kojima, and S. Sakurai Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis Alcohol Clin Exp Res 29 2005 264S 271S
50. T. Matsuyama, M. Uemura, M. Ishikawa, M. Matsumoto, H. Ishizashi, and S. Kato Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis Alcohol Clin Exp Res 31 2007 S27 S35
51. F. Peyvandi, S. Siboni, D. Lambertenghi Deliliers, S. Lavoretano, N. De Fazio, and B. Moroni Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation Br J Haematol 134 2006 187 195
52. Y. Park, A. Yoshioka, K. Kawa, H. Ishizashi, H. Yaqi, and Y. Yamamoto Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation Bone Marrow Transplant 29 2002 789 794
53. M. Matsumoto, K. Kawa, M. Uemura, S. Kato, H. Ishizashi, and A. Isonishi Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels Bone Marrow Transplant 40 2007 251 259
54. S. Ko, E. Okano, H. Kanehiro, M. Matsumoto, H. Ishizashi, and M. Uemura Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases Liver Transpl 12 2006 859 869
55. T. Kobayashi, H. Wada, M. Usui, H. Sakurai, T. Matsumoto, and T. Nobori Decreased ADAMTS13 levels in patients after living donor liver transplantation Thromb Res 124 2009 541 545
56. I. Pereboom, J. Adelmeijer, Y. Van Leeuwen, H.G. Hendriks, R.J. Porte, and T. Lisman Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation Am J Transplant 9 2009 1189 1196
57. J.J.B. Schnog, J.A.K. Hovinga, S. Krieg, S. Akin, B. Lämmle, and D.P. Brandjes ADAMTS13 activity in sickle cell disease Am J Hematol 81 2006 492 498
58. J. Chen, W.E. Hobbs, J. Le, P.J. Lenting, P.G. de Groot, and J.A. López The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma Blood 117 2011 3680 3683